SCHEMBL13796812

SCHEMBL13796812

O=S(=O)(NC[C@H]1CC[C@H](CNc2nc(Nc3ccc(Cl)cc3)c3ccccc3n2)CC1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NPY5R Q15761 14/20 0.53
▸ SLC6A4 P31645 2/20 0.50
▸ SOS1 Q07889 2/20 0.50
▸ AQP1 P29972 2/20 0.49
▸ ADRA2A P08913 4/20 0.47
▸ MCHR1 Q99705 4/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ NPY1R P25929 1/20 0.47
▸ NPY2R P49146 1/20 0.47
▸ NPY4R P50391 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ CNR1 P21554 2/20 0.45
▸ CNR2 P34972 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13795934 0.94 NPY5R (0.59) NPY5RSLC6A4SOS1AQP1ADRA2A
SCHEMBL13796430 0.90 NPY5R (0.54) NPY5RSLC6A4SOS1AQP1ADRA2A
SCHEMBL13795882 0.90 NPY5R (0.58) NPY5RSLC6A4SOS1AQP1ADRA2A
SCHEMBL13796852 0.89 NPY5R (0.66) NPY5RSLC6A4SOS1AQP1ADRA2A
SCHEMBL13796848 0.89 NPY5R (0.63) NPY5RSLC6A4SOS1AQP1ADRA2A
SCHEMBL13796720 0.89 NPY5R (0.53) NPY5RSLC6A4SOS1AQP1ADRA2A
SCHEMBL13795419 0.87 NPY5R (0.68) NPY5RSLC6A4SOS1AQP1ADRA2A
SCHEMBL13796719 0.86 NPY5R (0.54) NPY5RSLC6A4AQP1ADRA2AMCHR1
SCHEMBL13796994 0.86 NPY5R (0.57) NPY5RSLC6A4AQP1ADRA2AMCHR1
SCHEMBL13796658 0.86 NPY5R (0.57) NPY5RSLC6A4SOS1AQP1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544690-B2 MCH receptor antagonists TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-06-09 — — US disclosed
US-20070037836-A1 Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide TAISHO PHARMACEUTICAL CO., LTD. (JP) 2007-02-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037836-A1 Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide MCHR1, MCHR2, MC4R NPY5R 11/4885SLC6A4 73/4885SOS1 3357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback